Unexpected data from new studies show that direct-acting antiviral agents might promote tumour occurrence in patients with cirrhosis, or recurrence in patients with presumed cure of hepatocellular carcinoma. In view of the potential clinical implications, this controversy calls for a thorough and expeditious consideration of the hypothetical oncogenic activity of novel HCV drugs.
Refers to Conti, F. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J. Hepatol.http://dx.doi.org/10.1016/j.jhep.2016.06.015 (2016) | Cheung, M. C. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol.http://dx.doi.org/10.1016/j.jhep.2016.06.019 (2016)